118 related articles for article (PubMed ID: 38582963)
1. TALEN-mediated intron editing of HSPCs enables transgene expression restricted to the myeloid lineage.
Seclen E; Jang JC; Lawal AO; Pulicani S; Boyne A; Tkach D; Juillerat A; Duchateau P; Valton J
Mol Ther; 2024 Jun; 32(6):1643-1657. PubMed ID: 38582963
[TBL] [Abstract][Full Text] [Related]
2. Platelets are efficient and protective depots for storage, distribution, and delivery of lysosomal enzyme in mice with Hurler syndrome.
Dai M; Han J; El-Amouri SS; Brady RO; Pan D
Proc Natl Acad Sci U S A; 2014 Feb; 111(7):2680-5. PubMed ID: 24550296
[TBL] [Abstract][Full Text] [Related]
3. Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I.
Gomez-Ospina N; Scharenberg SG; Mostrel N; Bak RO; Mantri S; Quadros RM; Gurumurthy CB; Lee C; Bao G; Suarez CJ; Khan S; Sawamoto K; Tomatsu S; Raj N; Attardi LD; Aurelian L; Porteus MH
Nat Commun; 2019 Sep; 10(1):4045. PubMed ID: 31492863
[TBL] [Abstract][Full Text] [Related]
4. A Highly Efficacious PS Gene Editing System Corrects Metabolic and Neurological Complications of Mucopolysaccharidosis Type I.
Ou L; Przybilla MJ; Ahlat O; Kim S; Overn P; Jarnes J; O'Sullivan MG; Whitley CB
Mol Ther; 2020 Jun; 28(6):1442-1454. PubMed ID: 32278382
[TBL] [Abstract][Full Text] [Related]
5. Stable transgene expression in primitive human CD34+ hematopoietic stem/progenitor cells, using the Sleeping Beauty transposon system.
Sumiyoshi T; Holt NG; Hollis RP; Ge S; Cannon PM; Crooks GM; Kohn DB
Hum Gene Ther; 2009 Dec; 20(12):1607-26. PubMed ID: 19689196
[TBL] [Abstract][Full Text] [Related]
6. Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome.
Wang D; Zhang W; Kalfa TA; Grabowski G; Davies S; Malik P; Pan D
Proc Natl Acad Sci U S A; 2009 Nov; 106(47):19958-63. PubMed ID: 19903883
[TBL] [Abstract][Full Text] [Related]
7. Limited transgene immune response and long-term expression of human alpha-L-iduronidase in young adult mice with mucopolysaccharidosis type I by liver-directed gene therapy.
Di Domenico C; Di Napoli D; Gonzalez Y Reyero E; Lombardo A; Naldini L; Di Natale P
Hum Gene Ther; 2006 Nov; 17(11):1112-21. PubMed ID: 17044753
[TBL] [Abstract][Full Text] [Related]
8. Targeting a Pre-existing Anti-transgene T Cell Response for Effective Gene Therapy of MPS-I in the Mouse Model of the Disease.
Squeri G; Passerini L; Ferro F; Laudisa C; Tomasoni D; Deodato F; Donati MA; Gasperini S; Aiuti A; Bernardo ME; Gentner B; Naldini L; Annoni A; Biffi A; Gregori S
Mol Ther; 2019 Jul; 27(7):1215-1227. PubMed ID: 31060789
[TBL] [Abstract][Full Text] [Related]
9. Mucopolysaccharidosis Type I Phenotypically Corrected with Edited Hematopoietic Stem Cells: Instead of altering the IDUA gene, a protein was inserted in a repurposable place in the genome known as a "safe harbor locus".
Am J Med Genet A; 2020 Feb; 182(2):275-276. PubMed ID: 31943709
[No Abstract] [Full Text] [Related]
10. Hematopoietic Stem- and Progenitor-Cell Gene Therapy for Hurler Syndrome.
Gentner B; Tucci F; Galimberti S; Fumagalli F; De Pellegrin M; Silvani P; Camesasca C; Pontesilli S; Darin S; Ciotti F; Sarzana M; Consiglieri G; Filisetti C; Forni G; Passerini L; Tomasoni D; Cesana D; Calabria A; Spinozzi G; Cicalese MP; Calbi V; Migliavacca M; Barzaghi F; Ferrua F; Gallo V; Miglietta S; Zonari E; Cheruku PS; Forni C; Facchini M; Corti A; Gabaldo M; Zancan S; Gasperini S; Rovelli A; Boelens JJ; Jones SA; Wynn R; Baldoli C; Montini E; Gregori S; Ciceri F; Valsecchi MG; la Marca G; Parini R; Naldini L; Aiuti A; Bernardo ME;
N Engl J Med; 2021 Nov; 385(21):1929-1940. PubMed ID: 34788506
[TBL] [Abstract][Full Text] [Related]
11. Improved retroviral vector design results in sustained expression after adult gene therapy in mucopolysaccharidosis I mice.
Herati RS; Ma X; Tittiger M; Ohlemiller KK; Kovacs A; Ponder KP
J Gene Med; 2008 Sep; 10(9):972-82. PubMed ID: 18613275
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy for a mucopolysaccharidosis type I murine model with lentiviral-IDUA vector.
Di Domenico C; Villani GR; Di Napoli D; Reyero EG; Lombardo A; Naldini L; Di Natale P
Hum Gene Ther; 2005 Jan; 16(1):81-90. PubMed ID: 15703491
[TBL] [Abstract][Full Text] [Related]
13. Understanding and overcoming adverse consequences of genome editing on hematopoietic stem and progenitor cells.
Lee BC; Lozano RJ; Dunbar CE
Mol Ther; 2021 Nov; 29(11):3205-3218. PubMed ID: 34509667
[TBL] [Abstract][Full Text] [Related]
14. Genome editing in human hematopoietic stem and progenitor cells via CRISPR-Cas9-mediated homology-independent targeted integration.
Bloomer H; Smith RH; Hakami W; Larochelle A
Mol Ther; 2021 Apr; 29(4):1611-1624. PubMed ID: 33309880
[TBL] [Abstract][Full Text] [Related]
15. Myeloid/Microglial driven autologous hematopoietic stem cell gene therapy corrects a neuronopathic lysosomal disease.
Sergijenko A; Langford-Smith A; Liao AY; Pickford CE; McDermott J; Nowinski G; Langford-Smith KJ; Merry CL; Jones SA; Wraith JE; Wynn RF; Wilkinson FL; Bigger BW
Mol Ther; 2013 Oct; 21(10):1938-49. PubMed ID: 23748415
[TBL] [Abstract][Full Text] [Related]
16. Treatment of the mouse model of mucopolysaccharidosis I with retrovirally transduced bone marrow.
Zheng Y; Rozengurt N; Ryazantsev S; Kohn DB; Satake N; Neufeld EF
Mol Genet Metab; 2003 Aug; 79(4):233-44. PubMed ID: 12948739
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Testing of the Safety and Tolerability of Lentiviral Vector-Mediated Above-Normal Alpha-L-Iduronidase Expression in Murine and Human Hematopoietic Cells Using Toxicology and Biodistribution Good Laboratory Practice Studies.
Visigalli I; Delai S; Ferro F; Cecere F; Vezzoli M; Sanvito F; Chanut F; Benedicenti F; Spinozzi G; Wynn R; Calabria A; Naldini L; Montini E; Cristofori P; Biffi A
Hum Gene Ther; 2016 Oct; 27(10):813-829. PubMed ID: 27431943
[TBL] [Abstract][Full Text] [Related]
18. Different Human Immune Lineage Compositions Are Generated in Non-Conditioned NBSGW Mice Depending on HSPC Source.
Hess NJ; Lindner PN; Vazquez J; Grindel S; Hudson AW; Stanic AK; Ikeda A; Hematti P; Gumperz JE
Front Immunol; 2020; 11():573406. PubMed ID: 33193358
[TBL] [Abstract][Full Text] [Related]
19. Intranasal Adeno-Associated Virus Mediated Gene Delivery and Expression of Human Iduronidase in the Central Nervous System: A Noninvasive and Effective Approach for Prevention of Neurologic Disease in Mucopolysaccharidosis Type I.
Belur LR; Temme A; Podetz-Pedersen KM; Riedl M; Vulchanova L; Robinson N; Hanson LR; Kozarsky KF; Orchard PJ; Frey WH; Low WC; McIvor RS
Hum Gene Ther; 2017 Jul; 28(7):576-587. PubMed ID: 28462595
[TBL] [Abstract][Full Text] [Related]
20. ZFN-Mediated In Vivo Genome Editing Corrects Murine Hurler Syndrome.
Ou L; DeKelver RC; Rohde M; Tom S; Radeke R; St Martin SJ; Santiago Y; Sproul S; Przybilla MJ; Koniar BL; Podetz-Pedersen KM; Laoharawee K; Cooksley RD; Meyer KE; Holmes MC; McIvor RS; Wechsler T; Whitley CB
Mol Ther; 2019 Jan; 27(1):178-187. PubMed ID: 30528089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
